Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature

Naveen Pemmaraju; Koji Sasaki; Daniel Johnson; Naval Daver; Vahid Afshar-Kharghan; Merry Chen; Sairah Ahmed; Rivka R Colen; Michael Kwon; Yang Huh; Gautam Borthakur

doi:10.3389/fonc.2015.00029

Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature

Front Oncol. 2015 Feb 11:5:29. doi: 10.3389/fonc.2015.00029. eCollection 2015.

Authors

Affiliations

¹ Department of Leukemia, MD Anderson Cancer Center , Houston, TX , USA.
² Department of Internal Medicine, Louisiana State University , New Orleans, LA , USA.
³ Department of Benign Hematology, MD Anderson Cancer Center , Houston, TX , USA.
⁴ Department of Neuro-Oncology, MD Anderson Cancer Center , Houston, TX , USA.
⁵ Department of Stem Cell Transplantation, MD Anderson Cancer Center , Houston, TX , USA.
⁶ Department of Diagnostic Radiology, MD Anderson Cancer Center , Houston, TX , USA.
⁷ Department of Hematopathology, MD Anderson Cancer Center , Houston, TX , USA.

Abstract

Intracranial hemorrhage (ICH) is a common complication in acute myeloid leukemia (AML) patients with an incidence rate of 6.3% (1). Bleeding disorders related to disseminated intravascular coagulation (DIC) are common complications in AML cases (2). Recombinant activated Factor VII [rFVIIa (NovoSeven(®))] is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in patients with congenital FVII deficiency. Use of rFVIIa for the treatment of acute hemorrhage in patients without hemophilia has been successful (3, 4). Herein, we describe the successful use of rFVIIa in a patient with acute ICH in the setting of newly diagnosed AML.

Keywords: acute myeloid leukemia; intracranial hemorrhage; recombinant activated factor VII.